51856 Spesolimab rapidly improves quality of life in patients with generalized pustular psoriasis, as per Dermatology Life Quality Index scores: Data from the Effisayil 2 trial - 01/09/24
Doi : 10.1016/j.jaad.2024.07.1256
Georgios Kokolakis
Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, and Psoriasis Research and Treatment Centre, and Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Joseph F. Merola
Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Min Zheng
Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Richard B. Warren
Dermatology Centre, Salford Royal NHS Foundation Trust, and National Institute for Health and Care Research Manchester Biomedical Research Centre, The University of Manchester, Manchester, UK
Le texte complet de cet article est disponible en PDF.
| Commercial Support: The study was supported and funded by Boehringer Ingelheim. OPEN Health Communications (London, UK) provided writing, editorial, and formatting support, contracted and funded by Boehringer Ingelheim. |
© 2024
Publié par Elsevier Masson SAS.
Vol 91 - N° 3S
P. AB316 - septembre 2024 Retour au numéro
Article précédent
- 51395 Socioeconomic Status Correlates with Increased Use of Biologic Treatments and Improved Outcomes in Psoriasis Patients
- Ty Gilkey, Nathaniel Lampley, Ann Salvator, Anatha Padmanabhan
- 50516 Spironolactone treatment for dermatologic indications is not associated with clinically significant hypotension in a single-center retrospective study
- Rachel C. Hill, Yu Wang, Bilal Shaikh, Michael Ong, Paul J. Christos, Shari R. Lipner
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?